PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
about
Current state of immunotherapy for non-small cell lung cancer.Molecular chess? Hallmarks of anti-cancer drug resistanceCheckpoint Blockade in Lung Cancer and Mesothelioma.Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.Immune checkpoint inhibitors in lung cancer: an update.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Meta-analysis of the risk of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 therapies.Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Ramucirumab in the treatment of non-small cell lung cancer.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.Biomarkers for immunotherapy in bladder cancer: a moving target.Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Role of immune-checkpoint inhibitors in lung cancer.Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitorImmunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatmentTargeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
P2860
Q33645595-4981958E-05EF-4B52-9B49-2054183F8AB9Q36240941-BE609AAB-AC8B-4228-AEB0-85B31E56D63FQ36295004-D87C92D4-45E9-4599-882C-6CD1D74B22FDQ38610336-7254089B-661E-4BBA-8EB5-3B9177876573Q38611235-606B3D07-F66C-41F0-B675-2B8375C5EC6CQ38648979-BE3B1089-59A6-4C0B-B361-12BDE4CACB2EQ38686642-04DB0D48-2F96-436A-849B-2C26FF79CAF1Q38687631-8997C8C4-C041-4CD1-95B9-43EBB7481CD4Q38694662-1B9766AD-E9E4-4E71-9AE2-04D6C5DFE9B3Q38720801-B12AA418-5788-4608-A59D-800A0BC6D528Q39101223-67805C82-7397-4BFC-8F4F-672E17924E94Q39187442-C4270C6F-820D-4D8F-A57D-7AACDFC8B709Q39232340-B777F328-7750-407D-9E08-93C23683780AQ39237785-4555145E-283B-44DB-8562-7984087C2773Q40048521-5D833CB9-E24C-403A-8E5F-D747387C3313Q43396965-E72AAC5B-7CEE-4671-A700-577B3C492E73Q45952214-4C9B9F26-D3C0-4E07-8B2F-3746E6276D17Q47095389-CDC960ED-BA3A-4DF0-A674-687E58B29EE9Q47382727-710FB1F8-21FE-42C7-B466-01C47B2A0D7AQ48115656-4301B4A3-8CFF-42A5-A60B-D7CEA6FC55B1Q48275075-B42D546D-99C6-4110-BC15-FAC59389FA41Q48620065-DFBB2FA3-8173-4134-8A96-A4A601DE01ADQ49549096-8BF0856F-E48C-4A06-A584-3A24F1579FDBQ49959323-E594C444-3F3B-45D7-A1CF-A868417A360DQ49962956-9D6AEB9B-0BB9-4EB8-97AC-C7D5710D24B7Q50347895-9AF48555-AB93-4100-A790-FFB4D4D124B1Q51795706-F1E6B1F8-F812-43CB-9624-A023CA73432FQ52619047-67E9094B-8745-47FB-BFAC-E99FF8398A6FQ52699886-182BC89C-2A48-4D29-9538-00A17D8E81DAQ53835314-E8685289-DF12-4C0B-8A78-8A8EB46C1DA0Q55026862-15E7345A-D143-4030-BA34-78EAB1A55088Q55425751-95AD3E5F-24E2-486C-B345-0BB465B2B31DQ55717841-8C843916-63F4-438A-B366-D9F3C6A9B21DQ57062487-7C9B3069-4BBC-4D7E-B197-3211EE284640Q57069991-BEB27690-56BE-4819-9BE1-9DF34A55FA1FQ58783242-B0C98109-EBA4-474A-8551-229EC296CDEF
P2860
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@ast
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@en
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@nl
type
label
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@ast
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@en
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@nl
prefLabel
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@ast
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@en
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@nl
P2860
P3181
P1476
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
@en
P2093
Naiyer A Rizvi
P2860
P2888
P3181
P356
10.1186/S40425-016-0153-X
P407
P577
2016-01-01T00:00:00Z
P6179
1034928893